A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension.

Trial Profile

A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Angiotensin inhibitor vaccine (Primary) ; CoVaccineHT
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors BTG; Protherics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Apr 2009 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov record.
    • 02 Apr 2009 Dosing has been suspended for 2-3 months while safety data are reviewed, according to a BTG plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top